Of the forty-two patients diagnosed with non-mucinous ovarian cancer with no defined subtype, thirty were negative, three had a pathogenic BRCA1 mutation, six had a pathogenic BRCA2 mutation, one had a VUS mutation in the BRCA2 gene, and two had the moderate risk variant c.9976A>T (p.Lys3326Ter) in the BRCA2 gene (Table 1). This evidence concerns the gene BRCA2 and mucinous ovarian cancer.